AHRQ Tech Appraisal, Blues’ TEC Reveal Reservations With TMR Clinical Data
This article was originally published in The Gray Sheet
Executive Summary
The Blues' Technology Evaluation Center shares CMS' apparent dissatisfaction with existing clinical evidence for transmyocardial revascularization (TMR) performed with coronary artery bypass surgery
You may also be interested in...
TMR During Coronary Bypass: CMS Convenes MCAC To Reconsider Coverage
CMS should gather more prospective clinical trial data on transmyocardial revascularization during cardiac bypass surgery (TMR + CABG) before considering changes to its TMR Medicare coverage policy, the Society of Thoracic Surgery argues
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.